Sangeeta N. Bhatia - 01 May 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
01 May 2023
Net transactions value
-$202,004
Form type
4
Filing time
03 May 2023, 16:44:20 UTC
Previous filing
26 Oct 2022
Next filing
11 Aug 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +1,168 +29% $0.000000 5,208 01 May 2023 Direct F1
transaction VRTX Common Stock Sale $21,448 -62 -1.2% $345.93 5,146 02 May 2023 Direct F2, F3, F4
transaction VRTX Common Stock Sale $59,631 -172 -3.3% $346.69 4,974 02 May 2023 Direct F2, F3, F5
transaction VRTX Common Stock Sale $41,779 -120 -2.4% $348.16 4,854 02 May 2023 Direct F2, F3, F6
transaction VRTX Common Stock Sale $57,021 -163 -3.4% $349.82 4,691 02 May 2023 Direct F2, F3, F7
transaction VRTX Common Stock Sale $22,126 -63 -1.3% $351.20 4,628 02 May 2023 Direct F2, F3, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
F2 Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/17/2022.
F3 Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $345.93 (range $345.20 to $346.12).
F5 Open market sales reported on this line occurred at a weighted average price of $346.69 (range $346.31 to $347.03).
F6 Open market sales reported on this line occurred at a weighted average price of $348.16 (range $347.91 to $348.64).
F7 Open market sales reported on this line occurred at a weighted average price of $349.82 (range $349.17 to $350.08).
F8 Open market sales reported on this line occurred at a weighted average price of $351.20 (range $350.92 to $351.48).